Epigral (EPIGRAL) Fundamentals 2026 — P/E 14.8x, Revenue Analysis | SniperIQ
Epigral (EPIGRAL) is a India-listed Basic Materials company in Chemicals with a market capitalization of ₹4,922 Crore, trading at ₹1137.85 on the BSE. This SniperIQ fundamentals page covers Epigral's valuation (P/E 14.8x, P/B 2.2x), profitability (net margin 13.1%), revenue (₹2,495 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Epigral's market cap?
Epigral (EPIGRAL) has a market capitalization of approximately ₹4,922 Crore, trading at ₹1137.85 on the BSE. Market cap moves with the live share price.
What is Epigral's P/E ratio?
Epigral's trailing twelve-month P/E ratio is 14.8x, with a price-to-book (P/B) of 2.2x. Valuation multiples are best compared with Basic Materials sector peers rather than read in isolation.
How profitable is Epigral?
Epigral runs a net profit margin of 13.1%, a gross margin of 34.2%, and an operating margin of 15.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Epigral generate?
Epigral reported revenue of ₹2,495 Crore for fiscal year 2026, with net income of ₹332 Crore and earnings per share (EPS) of 76.95. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Epigral pay a dividend?
Epigral offers a trailing dividend yield of about 0.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Epigral financially healthy?
Epigral carries a debt-to-equity ratio of 0.26x and a current ratio of 1.16x, with a market beta of 0.19. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Epigral a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Epigral (EPIGRAL) the key facts are: market cap ₹4,922 Crore, P/E 14.8x, revenue ₹2,495 Crore, 52-week range 806.2-2114.3. Weigh valuation, profitability, growth, and balance-sheet strength against Basic Materials peers and form your own view.
Track Epigral's full fundamentals live
Get Epigral's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.